Author, Subjects, Keywords

Cited Author

 
 
   » By Author or Editor
 » Browse Author by Alphabet
 » By Journal
 » By Subjects
 » By Affiliations
 » By Type
 » By Year
 » By Latest Additions
 
 
   » By Author
 » Top 20 Authors
 » Top 20 Article
 » Top 20 Journal Cited
 » Top 20 Cited
 » Top 20 Author Cited
 » Usage Since Sept 2007


 
 
 

Login | Create Account

Rational Management of Differentiated Thyroid Cancer.

Das, Birendra Kishore and Biswal, Biswa Mohan and Bhavaraju, Venkata Murali Krishna (2006) Rational Management of Differentiated Thyroid Cancer. Malaysian Journal of Medical Sciences, 13 (2). pp. 45-52. ISSN 1394195X

Full text not available from this repository.

Official URL: http://www.medic.usm.my/publication/mjms/

Affiliations

Universiti Sains Malaysia, School of Medical Sciences, Dept. of Nuclear Medicine, Radiotherapy & Oncology
Universiti Sains Malaysia, School of Medical Sciences, Dept. of Nuclear Medicine, Radiotherapy & Oncology
Universiti Sains Malaysia, School of Medical Sciences, Dept. of Nuclear Medicine, Radiotherapy & Oncology

Abstract

Differentiated thyroid cancer ( DTC ) is usually not very common (incidence is about 1% of all cancers and women are more often affected than men). However, higher incidences has been reported in many parts of South East Asia particularly in iodine deficient areas. Unlike other solid tumors, DTC is potentially curable with documented survival rate of >90%. Even if the disease is not totally cured, through repeated high dose radio iodine therapy the progress of the disease can be controlled with significant improvement in quality of life for many years. This is possible if a proper and state of the art therapeutic approach is made. Since the incidence is relatively low, individual experience of treating physicians or centers is mostly inadequate leading to improper management with subsequent increase in morbidity and mortality. The purpose of this review is to evolve a rational management protocol for the treatment of thyroid cancer. Centers which do not have all facilities like high dose radio iodine therapy etc. may still follow the protocol by referring the patient for a particular step to another centre. What is needed is the awareness of the treating physician about the appropriate management of DTC. In recent years, there have been some important developments in the management of differentiated thyroid cancer like use of recombinant human thyrotropin (rhTSH), use of retinoic acid for redifferentiation etc. Some of these developments having practical relevance have been briefly mentioned.

Item Type:Journal
Keywords:Thyroid cancer management, Differentiated thyroid cancer, Radioiodine therapy in thyroid cancer
Subjects:R Medicine
ID Code:845

1. Engelken G., Hymmer U., Schenk P. et al. Strahlentherapie der Struma maligna Chirug 1976; 47:435-8.

2. Pandav C.S., Kochupillal N. Endemic goiter in India: Prevalence, etiology, attendant disabilities and control measure. Indian J Pediat 1982; 50: 259-71.

3. Emerick G.T Duh Q.Y., Siperstein A.E. et al. Diagnosis,

treatment and outcome of follicular thyroid Carcinoma Cancer 1993; 72: 3287-95.

4. Hedinger C., Williams E.D., Sobin L.H. The WHO histological classification of thyroid tumors : a commentary on the second edition Cancer 1989; 63: 908 – 11.

5. Mazzaferri E.L. Management of solitary thyroid noduleNEJM 1993; 328: 553-9.

6. Das B.K., Thirumurthi K., Gadru N. Fine Needle Aspiration Biopsy Techniques : Diagnostic accuracy and overall contribution in the management of thyroid nodules In : Thyroid cancer A Monogram published by BARC, Bombay 1985.

7. Brennan M.D., Bergstrath E.J., Van Heerden J.A. et al. Follicular thyroid cancer treated at the Mayo Clinic Mayo Clin. Proc. 1991; 66: 11-22.

8. Mazzaferri E.L. Carcinoma of follicular epithelium: radioiodine and other treatment and outcomes. In: Braverman LE, Utiger RD, eds. The thyroid Philadelphia: JB Lippincott 1991: 1138-65.

9. Beierwaltes W.H. The treatment of thyroid carcinoma with radioactive iodine. Semin. Nucl. Med. 1978; 8: 79-94.

10. Glanzmann, C.H., Horst W, Therapie des metastasierenden Schildrusenadenokarcinoms mit 131-Jod Strahlentherapie 1979; 155: 223-9.

11. Samaan N.A., Schultz P.N., Hickey R.C. et al. Well differentiated thyroid carcinoma and the result of various modalities of treatment J Clin. Endocrinol.Metab 1992; 75: 714-20.

12. De Groot L.J., Reilly M. Comparision of 30 and 50-mCi doses of iodine-131 for Thyroid ablation. Ann.Intern. Med. 1982; 96: 51-3.

13. Francesco L., Capezzone M., Angelini F. et al. Radioiodine treatment of metastatic differenciated thyroid cancer in patients on L-thyroxine, using recombinant human TSH European Journal of Endocrinology 2001; 144: 5 – 11.

14. Kohlfuerst S., Igere I., Lind P. Recombinant human hyrotropin is helpful in the follow up and 131 I therapy of patients with thyroid cancer : a report of the results and benefits using recombinant human thyrotropin in clinical routine. Thyroid 2005; 15(4): 371-6.

15. Robbins R.J., Robbins A.K. Clinical review 156: Recombinant human thyrotropin and thyroid cancer Management J Clin Endocrinol Metab 2003; 88(5):1933-8.

16. Mazzaferri E.L. Massoll N. Management of papillary and follicular (differentiated) thyroid cancer : New paradigms using recombinant human thyrotropin Endocr Relat Cancer 2002; 9(4): 227-47.

17. Goldman J.M. Line B.R. Aamodt R.I.et al. Influence of triiodothyronine withdrawal time on I 131 uptake post thyroidectomy for thyroid cancer. J Clin Endocrinol Metab 1980; 50(4): 734-9.

18. Serhal D.I., Nasrallah M.P., Arafah B.M. Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer. J Clin Endocrinol Metab. 2004; 89 (7): 3285-9.

19. Simon D., Korber C., Krausch M. et al. Clinical impact

of retinoids in differentiation therapy of advanced thyroid cancer : final results of a pilot study J Clin Endocrinol Metab. 2000; 85: 2028-33.

20. Coelho S.M., Corbo R., Buescu A. et al. Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma J Endocrinol Invest 2004; 27(4): 334-9.

21. Simon D., Kohrle J., Schmutzler C. et al. Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid : basics and first clinical results Exp Clin Endocrinol Diabetes 1996;104 Suppl 4:13-5.

22. Samaan N.A., Schultz P.N., Hickey R.C., et al. The Result of Various Modalities of Treatment of Differentiated Thyroid Carcinoma : A Retrospective Reviw of 1599 Patients J Clin Endocrinol Metb 1992; 75(3): 714-9.

23. Maxon III H.R., Englaro E.E., Thomas S.R. et al. adioiodine- 131 Therapy for Well-Differentiated tyroid Cancer – A Quantitative Radiation Dosimetric Approach : Outcome and Validation in 85 Patients The Journal of Nuclear Medicine 1992; 33(6): 1132-6.

4. Lin J.D., Kao P.F., Chao T.C. The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma The British Journal of Radiology, 1998; 71: 307-13.

25. Bal C.S., Ajay Kumar, Pant G.S. : Radioiodine Dose for Remnant Ablation in Differentiated Thyroid Carcinoma : A Randomised Clinical Trial in 509 Patients J Clin Endocrinol Metb 2004; 89(4): 1666-73 .

26. Teoh C.M, Rohaizak M., Chan K.Y. et al. Pre-ablative Diagnostic Whole-body Scan Following Total Thyroidectomy for Well- differentiated Thyroid Cancer : Is It necessary? Asian Journal of Surgery2005; 28(2): 90-6.

Repository Staff Only: item control page
 
 
 
 
 
   
© Copyright 2007 MyAIS Faculty of Computer Science and Information Technology, University of Malaya – All Rights Reserved. Malaysian Abstracting and Indexing System is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.